Advertisement

Document › Details
bioMérieux S.A.. (1/13/25). "Press Release: bioMérieux to Present at the 43rd Annual J.P. Morgan HealthCare Conference". Marcy l’Étoile.
bioMérieux, a world leader in the field in vitro diagnostics, today announces its participation in the 43rd Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, USA, from January 13 to 16, 2025.
Pierre Boulud, Chief Executive Officer of bioMérieux, will give a presentation on January 14, 2025, at 5:15 pm PT (02:15 am CET). A Q&A session will follow the presentation.
On this occasion, Pierre Boulud, will present an overview of bioMérieux together with the main drivers of its strategic plan, GO•28, presented last April, during the Capital Markets Day. The ambition is to deliver a profitable and sustainable growth with a +7% CAGR1 organic sales growth over the period 2024 / 2028 and an increase in CEBIT2 margin from 16.6% of sales in 2023 to 20% in 2028 at constant exchange rates and perimeter.
In addition, Pierre Boulud will provide an update on installations of BIOFIRE® and SPOTFIRE® in Q4 2024, respectively +500 net units and +900 units, and present bioMérieux’s recent acquisition of SpinChip, a Norwegian start-up dedicated to point-of-care immunoassays.
bioMérieux's presentation (in English) will be broadcasted live (audio only) using the following link: https://jpmorgan.metameetings.net/events/healthcare25/sessions/58370-
biomerieux/webcast?gpu_only=true&kiosk=true
The slides of the presentation will be made available on the company's website: www.biomerieux.com.
INVESTOR CALENDAR
Fourth-quarter 2024 sales and 2024 financial results March, 7th 2025
--------------------------------------
1CAGR: Compound Annual Growth Rate
2 CEBIT: Contributive operating income before non-recurring items: operating income before non-recurring items, excluding items relating to the amortization and impairment of intangible assets related to acquisitions and acquisition-related costs.
--------------------------------------
ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics for 60 years, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2023, revenues reached €3.7 billion, with over 93% of sales outside of France.
bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
Corporate website: www.biomerieux.com
CONTACTS
INVESTORS RELATIONS
Aymeric Fichet
Tel.: +33 (0)4 78 87 20 00
investor.relations@biomerieux.com
MEDIA RELATIONS
CORPORATE
Romain Duchez
Tel.: +33 (0)4 78 87 20 00
media@biomerieux.com
UNITED STATES
Liza Deckelbaum (SEEZ)
Tel. : (919) 521-0507
lizad@seeztoday.com
FRANCE
Laurence Heilbronn (Image 7)
Tel.: +33 (0)1 53 70 74 48
lheilbronn@image7.fr
Record changed: 2025-01-13 |
Advertisement

More documents for Mérieux (Group)
- [1] bioMérieux S.A.. (1/13/25). "Press Release: bioMérieux Strengthens Its Point of Care Presence with the Acquisition of the Immunoassay Start-up SpinChip". Marcy l’Étoile....
- [2] Mérieux NutriSciences Corporation. (10/7/24). "Press Release: Mérieux NutriSciences Enters Agreement to Acquire Worldwide Food Testing Business of Bureau Veritas". Chicago, IL....
- [3] bioMérieux S.A.. (10/19/23). "Press Release: bioMérieux Makes Strategic Investment in Oxford Nanopore". Oxford & Marcy-l’Etoile....
- [4] bioMérieux S.A.. (4/14/23). "Press Release: Oxford Nanopore and bioMérieux to Enter into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics". Oxford & Marcy-l’Etoile....
- [5] InDevR, Inc.. (1/17/23). "Press Release: InDevR Raises $9 Million in Series B Financing and Partners with bioMérieux". Boulder, CO....
- [6] Weezion SAS. (6/1/22). "Press Release: Weezion, a French MedTech Start-up, Announces Capital Investment from bioMérieux". Lyon....
- [7] bioMérieux S.A.. (3/18/22). "Press Release: bioMérieux Receives FDA 510(k) Clearance for Its VITEK MS PRIME New MALDI-TOF Mass Spectrometry Identification System". Marcy l’Étoile....
- [8] bioMérieux S.A.. (6/6/19). "Press Release: bioMérieux Increases Its Holding in Hybiome from 54% to 67%". Marcy l’Étoile....
- [9] bioMérieux S.A.. (4/24/19). "Press Release: bioMérieux – First-Quarter 2019 Business Review". Marcy l’Étoile....
- [10] bioMérieux S.A.. (4/15/19). "Press Release: “Global-PPS”, a Survey of Antibiotic Use and Bacterial Resistance in Hospitals Worldwide, Tops the 200,000 Patients". Marcy l’Étoile & Antwerp....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com
Advertisement

» top